Skip to content

Comaparison of effectiveness and safety of surgery versus local application of TCA ( tricholoroacetic acid) in treatment of abnormal eyelid fat deposits (xanthelasma palpebrum)

Safety and efficacy of surgical excision versus 70% Tricholoroacetic acid (TCA) topical application in xanthelasma palpebrum: a split face randomized trial. - NIL

Status
Active, not recruiting
Phases
Unknown
Study type
Interventional
Source
CTRI
Registry ID
CTRI/2024/10/074929
Enrollment
36
Registered
2024-10-08
Start date
Unknown
Completion date
Unknown
Last updated
2024-10-14

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Health Condition 1: O- Medical and Surgical

Interventions

Intervention1: Surgical excision arm: This will be a split face study in which Xanthlasma palpebrum (XP) lesions involving the upper and/or lower eyelids of one eye of each patient will be randomized

Sponsors

JIPMER Pondicherry
Lead Sponsor

Eligibility

Inclusion criteria

Inclusion criteria: ) Age 18 years or above 2) Patients with bilateral XP (involving at least one eyelid of both eyes) 3) XP involving one third or lesser of palpebral area in all the involved eyelids

Exclusion criteria

Exclusion criteria: 1) Patients with XP lesions with vertical height greater then one third of height of palpebral area (eyelids) will be excluded 2) Patients with XP lesions encroaching within 2 mm of medial or lateral canthus will be excluded 3) Patient with history of hypertrophic scars, keloids 4) Patients with coagulation disorders 5) Pregnancy and lactation Patients with extensive XP involving more than one third of palpebral area or vertical height greater then one third of height of palpebral area (eyelids) in any of the eyelids of any of the eye will be excluded owing to relative inefficacy of TCA in treating large XP lesions and also due to poten-tial difficulty in primary closure while doing surgical exci-sion of large lesions. Patients with XP lesions encroaching within 2 mm of medial or lateral canthus will be excluded to ensure safety of eyes during the procedures.

Design outcomes

Primary

MeasureTime frame
1) Number of XPU achieving complete clinical response (100 % reduction in size) in group A versus group B.Timepoint: week 12

Secondary

MeasureTime frame
Secondary outcomes 1) Percentage reduction in size of XPU. 2) Number of XPU achieving excellent , very good, good, moderate and poor clinical response. 3) Number of XPU achieving excellent, good and accepta-ble cosmetic improvement. 4) PGA for XPU in both groups 5) Adverse effects in both the groups XPU. 5) Number of days of post- operative pain in XPU. Timepoint: week 12

Countries

India

Contacts

Public ContactSheetanshu Kumar

Jawaharlal Institute of Postgraduate Medical Education and Research (JIPMER) Puducherry

kumar.sheetanshu@gmail.com9914211066

Outcome results

None listed

Source: CTRI (via WHO ICTRP) · Data processed: Feb 4, 2026